社区综合干预在慢性阻塞性肺疾病稳定期的疗效观察

Community Intervention in Chronic Obstructive Pulmonary Disease Efficacy of Stable Period

目的:观察社区综合干预在慢性阻塞性肺疾病(COPD)患者稳定期的疗效。方法:选取符合COPD诊断标准的患者76例,随机分为干预组38例和对照组38例,治疗起点为COPD处于稳定期。干预组进行社区综合干预,包括指导膳食、活动指导、氧疗、健康教育、社会心理支持、中医干预。对照组未实行社区综合干预。两组患者均给予常规口服少量平喘、祛痰药物治疗,分别于治疗开始前和治疗12个月后进行肺功能检查及6min步行试验并观察急性加重次数。结果:干预组与对照组相比,治疗前差异无统计学意义(P>0.05)。治疗12个月后干预组FEV1、FEV1/FVC及6min步行试验与治疗前相比差异有统计学意义(P<0.05),干预组治疗后FEV1、FEV1/FVC及6min步行试验与对照组治疗后相比差异有统计学意义(P<0.05)。并且干预组急性发作次数少于对照组。结论:社区综合干预对稳定期COPD患者有重要意义,可以减少慢性阻塞性肺疾病急性发作次数,提高患者生活质量,降低病死率。

Objective ： Watch the stable effect of community intervention in chronic obstructive pulmonary disease （COPD） patients. Methods ： 76 patients who meet the diagnostic criteria for COPD were randomly divided into intervention group and control group in 38 cases. All patients with COPD is in stable. The intervention group carries out community intervention, including guide meals and activities, oxygen therapy, health education, psychosocial support, traditional chinese medicine intervention. The control group did not interfere with community intervention. Two groups of patients were given a conventional oral smoothing asthma, eliminate sputum drug therapy, respectively, before treatment and after treatment for 12 months with pulmonary function tests and 6 min walking test then observe the number of acute exacerbation. Results ： The intervention group compared with the control group, no significant difference between pre-treatment （P〉0.05）. Treatment after 12 months intervention group bouth FEVI, FEVI/FVC and 6 min walking test compared with before treatment were significantly different （P 〈0.05）. Intervention group after treatment, both FEV1/FVC FEV1 and 6 min walk test and control group after treatment was statistically significant difference （P〈0.05）, and the acute episodes of intervention group less than control group. Conclusion ： Community intervention on patients with stable COPD is important, can reduce the chronic obstructive pulmonary disease with acute episodes, improve patient quality of life and reduce mortality.